DIFFERENT ANTI-VEGF AGENTS FOR THE TREATMENT OF DIABETIC MACULAR EDEMA IN PATIENTS WITH WORSE BASELINE VISUAL ACUITY – REAL WORLD EVIDENCE
DIFFERENT ANTI-VEGF AGENTS FOR THE TREATMENT OF DIABETIC MACULAR EDEMA IN PATIENTS WITH WORSE BASELINE VISUAL ACUITY – REAL WORLD EVIDENCE

Summary/Abstract: Introduction and goal: To determine whether there is a difference between the two drugs in the treatment of diabetic macular edema (DME) in patients with worse baseline BCVA (best corrected visual acuity) after one year of therapy. Material and methods: Retrospective analysis - comparison between ranibizumab 0.5 mg and aflibercept 2.0 mg in patients with BCVA deterioration 68-35 letters due to DME. Comparison of changes in BCVA, macular central subfield thickness (CST), number of injections. Results: 23 eyes (19 patients) - 13 eyes treated with ranibizumab, 10 eyes with aflibercept. Baseline CST 351.0 μm [334.5-442.0] (ranibizumab), 557.5 μm [441.8-615.8] (aflibercept), P<0.001. CST after treatment 286.0 μm [256.5-337.0], 369.0 μm [309.0-595.0] respectively, P=0.014. Improvement of BCVA (letters) +6.0 [2.0-12.5], +11.5 [9.0-15.3] respectively, P=0.054. Number of injections 7.0 [4.5-8.5], 9.0 [9.0-10.0] respectively, P=0.002. Conclusions: No difference was found between ranibizumab and aflibercept in visual acuity gain and macular thickness reduction after the first year of treatment in patients with worse baseline visual acuity due to DME. In comparison to ranibizumab, patients treated with aflibercept had thicker baseline maculae and were treated with more injections.

• Details
• Contents